This year alone about 62,000 Americans will be diagnosed with cancer of the oral cavity, pharynx, larynx and thyroid. More than 25 percent of oral cancers occur in people who do not smoke or have other risk factors.
Head and neck cancers arise from the cells that make up the face, mouth and throat. Because cancers in different locations behave differently, treatment depends on the cancer type and extent. Some common locations include:
Cancers arising in the brain or eyes are considered different from head and neck cancers (Please look at our Brain Cancer section). Treatment for head and neck cancer depends on several factors, including the type of cancer, the size and stage, its location, and your overall health. Surgery, radiation therapy and chemotherapy are the mainstays of treating head and neck cancer.
For many head and neck cancers, combining two or three types of treatments may be most effective. That's why it is important to talk with several cancer specialists about your care, including a surgeon, a radiation oncologist and a medical oncologist.
External beam radiation therapy involves a series of daily outpatient treatments to accurately deliver radiation to the cancer.
3-dimensional conformal radiotherapy (3D-CRT) combines multiple radiation treatment fields to deliver precise doses of radiation to the affected area. Tailoring each of the radiation beams to focus on the tumor delivers a high dose of radiation to the tumor and avoids nearby healthy tissue.
Intensity modulated radiation therapy (IMRT) is the most recent advance in the delivery of radiation. IMRT improves on 3D-CRT by modifying the intensity of the radiation within each of the radiation beams. This allows more precise adjustment of radiation doses to the tissues within the target area
The side effects you may experience will depend on the area being treated, the type of radiation used and whether or not you also received chemotherapy. Before treatment, your doctor will describe what you can expect.
Some patients experience minor or no side effects and can continue their normal routines.
If at any time you develop side effects, tell your doctor or nurse. He or she can give you medicine to help.
IRB # 1505016229 A First-in-Human Study of Repeat Dosing with REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination with Other Anti-Cancer Therapies in Patients with Advanced Malignancies NCT02383212
This study is currently recruiting participants.